Cytomegalovirus (CMV) infection remains a primary concern for recipients of allogeneic hematopoietic stem cell transplants (HSCTs) and kidney transplants, primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact of CMV infection in patients with HSCTs or kidney transplants, the interdisciplinary care team managing these patients must have guidance on incorporating novel antiviral therapies into prevention and treatment schemas for CMV. In this recorded CME Outfitters Grand Rounds series, expert faculty will appraise the burden and impact of CMV infection on recipients of HSCTs or kidney transplants, and will review and translate novel antiviral therapies for prevention and treatment of CMV in the real-world setting.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/cytomegalovirus-in-stem-cell-and-kidney-transplant-overcoming-the-limitations-of-conventional-antiviral-therapy/
- Start Date: 2024-08-13 05:00:00
- End Date: 2024-08-13 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Merck (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Infectious Disease, Internal Medicine